Iluvien and the Future of Ophthalmic Drug Delivery Systems
I have just written and placed online an in-depth writeup about a new drug delivery system, that should obtain FDA marketing approval by the end of this year. It has the potential to treat diabetic macular edema for up to three years. The drug system, the size of a grain of rice, is called Iluvien and is from Alimera Sciences. It is one a group of new ophthalmic sustained drug delivery systems that are currently on or about to enter the market for treating ophthalmic diseases, especially in the retina.
In addition to the story of Iluvien, I have listed a group of sustained drug delivery system under development for various other ophthalmic diseases.